Experimental Melanoma Treatment RP1 FDA Review
An FDA advisory committee voted 10-3 in favor of recommending Replimune's experimental melanoma treatment RP1 on July 30, 2026, moving it closer to a potential August 2, 2026 approval despite some FDA scientists' concerns about the study data. As of July 31, 2026, the FDA CTGTAC reviewed RP1/Nivolumab data, using the accelerated approval of lifileucel (Amtagvi) in 2024 as a precedent. Real-world data in July 2026 showed lifileucel (Amtagvi) achieved a 48.8% objective response rate (ORR) in advanced melanoma patients previously treated with immune checkpoint inhibitors and targeted therapies, with a 52% ORR for patients with two or fewer prior lines of therapy. Iovance Biotherapeutics projects 2026 full-year revenue for Amtagvi between $350M and $370M, with over 1,500 patients treated.
Timeline
Want updates on this thread?
Track this storyTimeline of developments
August 2026 — 2 developments
FDA Approves Tudriqev and Nivolumab Combination for Advanced Melanoma
The FDA has approved Tudriqev (vusolimogene oderparepvec-wtpg) in combination with nivolumab for unresectable advanced cutaneous melanoma. This approval is for patients who progressed after a PD-1 blocking antibody-based regimen. The therapy demonstrated a 24.2% objective response rate with a median duration of response of 14.1 months.
FDA Panel Backs RP1 for Melanoma; Obsidian Therapeutics Eyes 2027 Data
The FDA's Cellular, Tissue, and Gene Therapies Advisory Committee supported RP1 consideration for advanced melanoma, citing significant unmet need. The IGNYTE trial reported an objective response rate of 33.6% with a median duration of response of 24.8 months and median overall survival of 32.9 months. Obsidian Therapeutics anticipates presenting melanoma registration-enabling data for OBX-115 by the end of 2027.
July 2026 — 11 developments
FDA Reviews RP1/Nivolumab Data for Advanced Melanoma, Citing Lifileucel Approval as Precedent
On July 31, 2026, the FDA CTGTAC reviewed RP1/Nivolumab data in advanced melanoma, using the accelerated approval of lifileucel (Amtagvi) in 2024 as a precedent. This review highlights ongoing efforts to evaluate and approve novel treatments for advanced melanoma.
FDA Panel Recommends Experimental Melanoma Treatment RP1 for Approval
An FDA advisory committee voted 10-3 in favor of recommending Replimune's experimental melanoma treatment RP1 on July 30, 2026. This recommendation moves RP1 closer to a potential August 2, 2026 approval date, despite some FDA scientists' concerns about the study data.
FDA Discusses Lifileucel for Melanoma; Community Health Network Expands Access to TIL Therapy
An FDA briefing document released on July 30, 2026, discusses lifileucel as a treatment option for unresectable or metastatic melanoma. Community Health Network has also expanded access to lifileucel, the first FDA-approved tumor-infiltrating lymphocyte (TIL) therapy for advanced melanoma, at its Stem Cell Transplant and Cellular Therapy Institute in Indianapolis.
New Strategy Explored to Halt T Cell Exhaustion and Boost Cancer Therapies
A new strategy is being explored that may halt T cell exhaustion and boost therapy, with potential applications for melanoma treatment. This includes research into checkpoint inhibitors, CAR T cell therapy, and TIL therapy. The development was published on July 23, 2026.
Iovance Biotherapeutics Withdraws Amtagvi Application in Europe Due to EMA Concerns
Iovance Biotherapeutics withdrew its marketing authorization application for Amtagvi in Europe in July 2025. The European Medicines Agency (EMA) had raised concerns regarding the drug's low response rate in the main study, safety issues leading to patient deaths, and insufficient data for the proposed dosage.
Lifileucel (Amtagvi) Shows 48.8% Response Rate in Real-World Advanced Melanoma Data
Real-world data released in July 2026 demonstrates that lifileucel (Amtagvi) achieved a 48.8% objective response rate (ORR) in advanced melanoma patients previously treated with immune checkpoint inhibitors and targeted therapies. Patients receiving Amtagvi with two or fewer prior lines of therapy showed a higher ORR of 52%, suggesting earlier intervention may enhance efficacy.
Engineered TIL Therapy Shows High Response Rate in Advanced Melanoma Patients
Engineered TIL therapy OBX-115 has shown a 67% response rate in patients who previously failed combination immunotherapy. Senti Biosciences is also developing controllable, armored TIL therapies for solid tumors, expanding the application of TIL therapy in traditionally immunotherapy-resistant cancers.
New Study Identifies Potential Tailored Drug Combinations for Advanced Melanoma
Researchers at The University of Texas MD Anderson Cancer Center have identified a potential method to tailor drug combinations for treatment-resistant advanced melanoma by blocking BCL2 family proteins. Studies are ongoing to explore TIL therapy in various contexts, including combination strategies with other immunotherapies and its application in other solid tumors.
New Feeder-Free TIL Expansion System Promises Safer, More Accessible Cancer Immunotherapy
A new feeder-free tumor-infiltrating lymphocyte (TIL) expansion system has been published, potentially making advanced cancer immunotherapy safer and more accessible by simplifying manufacturing and lowering costs. This approach may reduce reliance on high-dose IL-2 and explore low-dose PD-1 blockade as an alternative, addressing safety concerns associated with current TIL therapy.
Iovance Projects $350M-$370M Amtagvi Revenue, Over 1,500 Patients Treated
Iovance Biotherapeutics projects 2026 full-year revenue for Amtagvi between $350M and $370M, with over 1,500 patients treated across multiple countries. Real-world data shows an Objective Response Rate (ORR) of up to 52% in advanced melanoma patients. The company is also advancing next-generation TIL therapies and exploring applications in other cancer types.
FDA Accepts Resubmission for Advanced Melanoma Treatment RP1, Sets Review Dates
The FDA has accepted a resubmission of a biologics license application for vusolimogene oderparepvec (RP1) in combination with nivolumab for advanced melanoma. An advisory committee meeting is scheduled for late July 2026, with a target review date of August 2, 2026.
June 2026 — 8 developments
TIL Therapy Implementation Detailed at Oncology Pharmacists Meeting
A presentation at the Oncology Pharmacists Connect meeting detailed the safe implementation of tumor-infiltrating lymphocyte (TIL) therapy at an academic cancer center, emphasizing the crucial role of clinical pharmacists in coordinating care and ensuring medication safety. This follows Australia's conditional approval of Amtagvi for advanced melanoma.
Amtagvi (lifileucel) Gains Conditional Approval in Australia; Pioneers Receive Tang Prize
Amtagvi (lifileucel) received conditional approval in Australia in June 2026, marking the first T-cell therapy for a solid tumor approved in the country. In June 2026, Drs. Steven A. Rosenberg, Michel Sadelain, and Carl H. June were jointly awarded the Tang Prize in Biopharmaceutical Science for their foundational work in TIL and CAR-T therapies.
Real-World Safety and Operational Challenges of Lifileucel TIL Therapy Discussed
Real-world safety outcomes with lifileucel in advanced melanoma patients were discussed at ASCO 2026, revealing prolonged cytopenias and post-treatment infections in some cases, though organ dysfunction and immune-related toxicities were low. Researchers suggested adjusting the lymphodepleting chemotherapy regimen might improve the safety profile of lifileucel treatment. Significant logistical challenges, including referral processes and manufacturing timelines up to 60 days, are crucial for the successful implementation of TIL therapies.
Multiple US Health Centers Expand Access to TIL Therapy for Advanced Melanoma
Multiple healthcare institutions, including Corewell Health, NYU Langone, and Fox Chase Cancer Center, are now offering or expanding access to TIL therapy for advanced melanoma patients. This development broadens the availability of this cutting-edge treatment beyond regulatory approvals and clinical trial presentations.
New TIL Therapy OBX-115 Shows 67% Response Rate in Advanced Melanoma Trial
The phase 1/2 Agni-01 trial presented at the 2026 ASCO Annual Meeting showed encouraging efficacy for OBX-115 engineered TIL cell therapy in patients with advanced nonuveal melanoma. Among 15 patients treated at the recommended phase 2 dose, the objective response rate (ORR) was 67%, with a manageable safety profile that appears to differentiate from the current standard TIL therapy, lifileucel.
TIL Therapy Advances Highlighted at ASCO 2026, Showing Improved Response Rates
Advances in TIL therapy were highlighted at the 2026 ASCO Meeting, including IL-15-enhanced approaches aimed at reducing toxicity and expanding applications to traditionally resistant tumors. A novel therapy from Obsidian demonstrated a 63% response rate and a 93% disease control rate. These developments suggest broader progress in TIL therapy beyond Amtagvi.
Amtagvi Shows Higher Real-World Response Rate; New Trials Underway
Real-world data presented at the 2026 Tandem Meetings showed Amtagvi achieved a 44% objective response rate (ORR) in advanced melanoma patients, an improvement over the 31% ORR from clinical trials. Iovance Biotherapeutics is also investigating Amtagvi in frontline advanced melanoma and other solid tumor types, and has received Investigational New Drug (IND) clearance for a new IL-12 tethered TIL therapy.
Australia Approves Lifileucel (Amtagvi) for Advanced Melanoma Treatment
Australia's Therapeutic Goods Administration (TGA) has granted conditional approval for Amtagvi (lifileucel) for the treatment of advanced melanoma. This marks the third global marketing authorization for the therapy and the first T-cell therapy approved in Australia for a solid tumor cancer.
May 2026 — 2 developments
Iovance Biotherapeutics raises 2026 revenue forecast driven by Amtagvi sales
Iovance Biotherapeutics reported strong first-quarter 2026 financial results, with total revenue of approximately $71 million, a 45% year-over-year increase. Amtagvi (lifileucel) contributed around $60 million in U.S. revenue, leading Iovance to revise its full-year 2026 revenue forecast upwards to $350-$370 million.
Amtagvi shows 20% five-year survival rate in advanced melanoma patients
Recent analyses of the Phase 2 C-144-01 trial for Amtagvi (lifileucel) revealed a 20% five-year survival rate in advanced melanoma patients previously treated with checkpoint inhibitors. The therapy demonstrated a 31.4% objective response rate with a median duration of response of 36.5 months, and nearly a third of responders maintained their response at the five-year mark.
April 2026 — 1 developments
Obsidian Therapeutics and Galera Therapeutics Merge to Advance OBX-115 TIL Therapy
Obsidian Therapeutics and Galera Therapeutics announced a merger in mid-April 2026 to advance OBX-115, a next-generation TIL therapy. This merger aims to improve upon existing treatments by potentially eliminating the need for high-dose interleukin-2 and enabling outpatient administration.
March 2026 — 2 developments
FDA raises concerns over Amtagvi's promotional materials regarding efficacy claims
The FDA issued a letter in March 2026 regarding promotional materials for Amtagvi (lifileucel), expressing concerns about potentially misleading efficacy claims, particularly concerning overall survival data from single-arm studies.
Lifileucel TIL therapy shows 44% response rate in real-world data at 2026 Tandem Meetings
Real-world data presented at the 2026 Tandem Meetings indicated an overall response rate of 44% for lifileucel TIL therapy, with higher responses observed in patients treated earlier in their disease course. The 8th TIL Therapies Summit in 2026 focuses on advancing TIL therapy for solid tumors beyond melanoma.
February 2026 — 7 developments
Iovance Biotherapeutics receives FDA Fast Track designation for lifileucel in lung cancer
Iovance Biotherapeutics has received FDA Fast Track designation for its lifileucel (TIL) therapy in non-small cell lung cancer. This designation expands the potential applications of lifileucel beyond its current focus on sarcomas and melanoma. The company is also planning a registrational trial for lifileucel in soft tissue sarcomas.
Iovance Biotherapeutics reports positive early data for lifileucel in soft tissue sarcomas
Iovance Biotherapeutics announced positive early pilot data for lifileucel (Amtagvi) in soft tissue sarcomas, showing a 50% confirmed objective response rate in early evaluable patients. Ochsner MD Anderson Cancer Center has also begun offering TIL therapy for advanced melanoma. Iovance reported approximately $220 million in Amtagvi sales in the U.S. for 2025.
Iovance Biotherapeutics announces positive early data for lifileucel in sarcoma trial
Iovance Biotherapeutics announced positive early data from a pilot clinical trial of lifileucel (TIL cell therapy) in patients with advanced undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated liposarcoma (DDLPS). The trial, supported by Iovance and led by Memorial Sloan Kettering Cancer Center, showed compelling response rates in patients refractory to frontline treatments. Iovance plans to initiate a registrational trial in the second quarter of 2026.
Iovance Biotherapeutics announces positive lifileucel trial results for advanced soft tissue sarcomas
Iovance Biotherapeutics announced positive results from its first clinical trial of lifileucel (Amtagvi) TIL cell therapy in patients with advanced soft tissue sarcomas. The trial showed compelling response rates, demonstrating potential to address a significant unmet need in patients refractory to frontline treatments. Iovance plans to initiate a registrational trial in the second quarter.
Vanderbilt-Ingram Cancer Center treats first patient with TIL therapy for melanoma
Vanderbilt-Ingram Cancer Center has treated its first patient in a newly launched tumor-infiltrating lymphocyte (TIL) therapy program. This personalized treatment involves isolating, expanding, and re-infusing a patient's own white blood cells to fight tumors. The therapy is currently approved and marks a new institutional application of TIL therapy for melanoma.
Lifileucel therapy shows improved response rates in advanced melanoma patients
Retrospective analysis of lifileucel (Amtagvi) therapy in advanced melanoma patients shows an objective response rate (ORR) of 44% and a disease control rate (DCR) of 73%. These real-world data exceed the ORR of 31% from the clinical trial that supported its accelerated FDA approval. A separate study also indicates that while a portion of referred patients proceed to TIL therapy, those who receive it show improved overall survival.
Dr. Asaf Madi awarded grant for melanoma TIL therapy research
The Israel Cancer Research Fund and the Cancer Research Institute awarded Dr. Asaf Madi a new grant to research refining tumor-infiltrating lymphocyte (TIL) therapy, focusing on predicting patient responses and overcoming drug resistance in melanoma.
December 2025 — 1 developments
NICE reviews FDA-approved immunotherapy Lifileucel for advanced melanoma in UK
Lifileucel, an FDA-approved personalized immunotherapy for advanced melanoma, is currently undergoing a review process with the National Institute for Health and Care Excellence (NICE) in the UK.
October 2025 — 1 developments
Discussion highlights innovation in next-generation engineered TILs
Further discussion on next-generation engineered TILs, including CRISPR gene editing and IL-2 toxicity elimination, highlights ongoing innovation in the field.
September 2025 — 1 developments
2025 ASCO Annual Meeting Highlights Advancements in TIL Therapy for Solid Tumors
The 2025 ASCO Annual Meeting showcases significant advancements in TIL therapy, including novel monotherapies (e.g., LM103, OBX-115, GT101, GT300, GT201, HS-IT101) and combination regimens for various solid tumors.
July 2025 — 1 developments
American Cancer Society explains TIL therapy, its use of immune cells to fight cancer
The American Cancer Society provides an overview of TIL therapy, explaining how it uses a patient's own immune cells to fight cancer and its potential benefits, including long-lasting responses.
June 2025 — 1 developments
Lifileucel five-year follow-up trial results published
Five-year follow-up trial results for Lifileucel are published, providing further long-term efficacy data for the approved therapy.
May 2025 — 1 developments
MedStar Georgetown University Hospital Offers Breakthrough TIL Therapy for Metastatic Melanoma
MedStar Georgetown University Hospital is now offering breakthrough Tumor-Infiltrating Lymphocyte (TIL) therapy for metastatic melanoma patients who have not responded to previous treatments. This marks a new phase in the therapy's availability to patients.
December 2024 — 1 developments
Lifileucel incorporated into 2024 NCCN Guidelines for advanced melanoma
Lifileucel is formally incorporated into the 2024 NCCN Guidelines as a preferred second-line regimen for advanced melanoma, solidifying its place in standard oncology practice.
November 2024 — 1 developments
Dr. Allison Betof Warner Discusses TIL Therapy for Advanced Melanoma
Dr. Allison Betof Warner discusses TIL therapy for advanced melanoma, highlighting its potential to overcome resistance to other therapies and its role in the future of melanoma care.
October 2024 — 1 developments
Industry Report Highlights FDA Approval of Lifileucel and Expanding TIL Therapy Market
An industry insight report discusses the FDA approval of Lifileucel, the expanding pipeline of over 75 TIL-based therapies, and more than 100 clinical trials globally, projecting significant market growth.
May 2024 — 2 developments
TIL Therapy: From Discovery to FDA Approval of Lifileucel and Ongoing Research
An article details the 30+ year journey of TIL therapy, from its discovery to the recent FDA approval of Lifileucel, and discusses ongoing research to enhance its efficacy and expand applications.
Stanford Cancer Institute Highlights Promise of TIL Therapy for Solid Tumors
Stanford Cancer Institute highlights the promise of TIL therapy, noting its potential for a wide array of solid tumors beyond melanoma and the significant advancements in the past 5-10 years that made it a viable treatment option.
April 2024 — 1 developments
Stanford Cancer Institute performs world's first commercial Lifileucel infusion for advanced melanoma
Stanford Cancer Institute performs the world's first commercially approved infusion of Lifileucel for advanced melanoma, marking its entry into routine clinical practice.
March 2024 — 1 developments
National Cancer Institute Publishes Blog Post on FDA Approval of Lifileucel
The National Cancer Institute publishes a blog post detailing the historic FDA approval of Lifileucel (Amtagvi), emphasizing its significance after decades of research.
February 2024 — 5 developments
New TIL Therapies Show Promise: Phase 3 Results for HBI-8000, Early Data for OBX-115, and Trial Initiation for CC-38
HUYABIO International announced positive Phase 3 results for HBI-8000 in combination with nivolumab for advanced melanoma, showing improved progression-free survival. Additionally, next-generation TIL therapy OBX-115 has shown promising early data in advanced melanoma patients who progressed on immunotherapy. CuraCell has also initiated a Phase I/IIa clinical trial for its TIL therapy CC-38, expanding its application to metastatic colorectal and prostate cancer.
Lifileucel (Amtagvi) Shows Durable Efficacy and New Expansion System Developed
Long-term data from the C-144-01 study show lifileucel (Amtagvi) maintains efficacy and a favorable safety profile in advanced melanoma patients, with a median duration of response of 36.5 months. Real-world data indicate a robust response rate of 44%, supporting its earlier consideration in treatment. Additionally, a new feeder-free TIL expansion system has been developed, potentially lowering costs and improving accessibility by reducing reliance on high-dose IL-2 and feeder cells.
Scientists Capture Macrophages Attacking Melanoma Cells; Amtagvi Shows 44% ORR
Scientists have captured, for the first time, immune cells (macrophages) actively attacking and engulfing live melanoma cells, a discovery that could open new avenues for melanoma treatment. Real-world data presented in early 2026 also indicates lifileucel (Amtagvi) achieved an objective response rate (ORR) of 44% in advanced melanoma patients, with earlier intervention showing higher response rates.
Study finds reduced-dose lymphodepleting regimen safe for lifileucel TIL therapy in metastatic melanoma
A recent study suggests lifileucel (Amtagvi) TIL therapy can be safely and effectively administered to high-risk metastatic melanoma patients using a reduced-dose lymphodepleting conditioning regimen. This modification may broaden eligibility for the treatment, which was previously inaccessible to some patients with poor performance status.
FDA grants accelerated approval to Lifileucel for advanced melanoma, first TIL therapy for solid tumor
The FDA grants accelerated approval to Lifileucel (Amtagvi) for the treatment of unresectable or metastatic melanoma in patients previously treated with other therapies, marking the first FDA-approved TIL therapy and the first cell-based immunotherapy for a solid tumor.
December 2023 — 1 developments
Researchers report 50% of Lifileucel patients alive four years post-treatment
Researchers report that nearly 50% of patients treated with investigational Lifileucel were alive four years post-treatment, with the median duration of response not yet reached, indicating potential for long-term benefits.
January 2023 — 1 developments
TIL Therapy Shows Longer Progression-Free Survival in Advanced Melanoma Patients
A report highlights that TIL therapy shows significantly longer progression-free survival in stage IIIC and IV melanoma patients compared to current recommended therapies, with some studies reporting a 50% overall response rate.
January 2022 — 1 developments
Studies show TIL therapy effective against refractory metastatic melanomas
Studies show TIL therapy to be effective against metastatic melanomas that are refractory to prior treatments, yielding superior outcomes compared to ipilimumab.
January 2021 — 1 developments
Iovance Biotherapeutics reports 80% disease control rate in Lifileucel Phase II melanoma trial
Iovance Biotherapeutics successfully conducts Phase II trials (LN-144) for Lifileucel in advanced melanoma patients who have progressed after immune checkpoint inhibitor treatment, demonstrating an 80% disease control rate.
January 2020 — 1 developments
Rosenberg and colleagues identify stem-like lymphocytes as key to antitumor activity
Rosenberg and colleagues identify a specific subset of TILs, known as stem-like lymphocytes, as being responsible for antitumor activity, enhancing understanding of TIL efficacy.
January 2017 — 1 developments
TIL therapy successfully treats uveal melanoma
TIL therapy is reported to be successful in treating uveal melanoma, a rare and refractory form of the disease.
January 2011 — 1 developments
National Cancer Institute partners with Iovance Biotherapeutics to advance TIL therapy development
The National Cancer Institute enters a cooperative research agreement with Iovance Biotherapeutics to advance the development of TIL therapy, including larger clinical trials and manufacturing infrastructure.
January 2009 — 1 developments
Moffitt Cancer Center First Outside NCI to Offer TIL Therapy for Melanoma
Moffitt Cancer Center becomes the first institution outside the NCI to offer TIL therapy to melanoma patients, adopting the NCI protocol.
January 2000 — 2 developments
New Method Developed for Culturing TILs, Improving Therapy Practicality
A simplified method for culturing TILs is developed, helping to keep the cells active for longer and improving the therapy's practicality.
Researchers find lymphodepleting chemotherapy boosts TIL therapy response in melanoma patients
Researchers discover that lymphodepleting chemotherapy prior to TIL infusion significantly increases response rates, leading to a 56% response rate in heavily treated metastatic melanoma patients.
January 1994 — 1 developments
Expanded TILs Clinical Trial Shows 34% Response Rate in Metastatic Melanoma Patients
Final results from an expanded clinical trial involving 86 metastatic melanoma patients treated with TILs are published, showing a 34% response rate.
January 1988 — 1 developments
Rosenberg and colleagues begin first experimental human TIL therapy for metastatic melanoma
The first experimental use of TIL therapy in humans begins, with Rosenberg and colleagues treating 20 patients with metastatic melanoma, showing promising preliminary results of tumor regressions.
January 1986 — 1 developments
NCI's Dr. Steven Rosenberg Discovers Tumor-Infiltrating Lymphocytes (TILs) and Develops Expansion Protocol
Dr. Steven Rosenberg and colleagues at the National Cancer Institute (NCI) discover tumor-infiltrating lymphocytes (TILs) in human tumors and develop a protocol to expand them in the lab, demonstrating their ability to cause tumor regression in mice.